Ascendis Pharma A/S

Common Name

Ascendis Pharma

Country

Denmark

Sector

Healthcare

Industry

Biotechnology

Employees

1,017

Ticker

ASND

Exchange

NASDAQ/NGS

Website

ascendispharma.dk

Description

Ascendis Pharma A/S is a biopharmaceutical company that focuses on developing innovative drug therapies for unmet medical needs. The company employs its proprietary TransCon technology platform to cre... Show more

Income Statement Balance Sheet Group Entities

Ascendis Pharma's Financial Statements Preview

Below are the financial statements of Ascendis Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?

Learn More

All figures in millions of EUR	2024 as of 2024-12-31	2023 as of 2023-12-31	2023 as of 2023-01-01
Assets	—	—	—
Non-current assets	—	—	—
Intangible assets	4.03^a	4.42^a	4.83^a
Property, plant and equipment	98.71^a	110.63^a	129.1^a
Investments in associates	13.58^a	5.69^a	22.93^a
Other receivables	2.32^a	2.13^a	1.92^a
Marketable securities	0^a	0^a	7.49^a
Non-current assets	118.63^a	122.87^a	166.27^a
Current assets	—	—	—
Inventories	295.61^a	208.93^a	130.67^a
Trade receivables	166.28^a	35.87^a	11.91^a
Income tax receivables	1.78^a	0.8^a	0.88^a
Other receivables	9.39^a	19.1^a	12.83^a
Prepayments	28.27^a	38.58^a	31.72^a
Marketable securities	0^a	7.28^a	290.69^a
Cash and cash equivalents	559.54^a	392.16^a	444.77^a
Current assets	1,060.86^a	702.72^a	923.47^a
Total assets	1,179.5^a	825.59^a	1,089.74^a
Equity and liabilities	—	—	—
Equity	—	—	—
Share capital	8.15^a	7.75^a	7.68^a
Distributable equity	-113.86^a	-153.45^a	255.67^a
Total equity	-105.71^a	-145.7^a	263.35^a
Non-current liabilities	—	—	—
Borrowings	365.08^a	223^a	95.4^a
Contract liabilities	5^a	5.95^a	14.21^a
Deferred tax liabilities	7.26^a	5.83^a	0^a
Non-current liabilities	377.34^a	234.78^a	109.61^a
Current liabilities	—	—	—
Convertible notes, matures in April 2028 borrowings	458.21^a	407.1^a	399.19^a
Derivative liabilities	150.67^a	143.3^a	157.95^a
Other current liabilities	—	—	—
Borrowings	33.33^a	14.17^a	13.79^a
Contract liabilities	0.94^a	1.18^a	0^a
Trade payables and accrued expenses	96.39^a	94.57^a	101.03^a
Other liabilities	67.96^a	41.18^a	31.99^a
Income tax payables	1.22^a	2.3^a	5.49^a
Provisions	99.15^a	32.72^a	7.34^a
Other current liabilities	298.99^a	186.12^a	159.64^a
Current liabilities	907.86^a	736.51^a	716.78^a
Total liabilities	1,285.2^a	971.28^a	826.39^a
Total equity and liabilities	1,179.5^a	825.59^a	1,089.74^a

Download Data

Verified Sources Behind Ascendis Pharma’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ascendis Pharma’s data sources below and access millions more through our Disclosure Search.

a. Ascendis Pharma's Annual Report 2024

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Ascendis Pharma A/S

Ascendis Pharma's Financial Statements Preview

Verified Sources Behind Ascendis Pharma’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

Genmab A/S

GN Store Nord A/S

H Lundbeck A/S

Ambu A/S

Demant A/S

Novo Nordisk A/S